Denecimig shows consistent safety and efficacy across age groups in hemophilia A trial

Denecimig, Novo Nordisk's subcutaneous non-factor hemophilia A therapy, showed consistent safety and efficacy across paediatric and adult cohorts in the FRONTIER4 extension trial (426 participants), with 89% of children achieving zero treated bleeds and annualized bleeding rates of 0.37 for children and 0.75 for adults. The drug, under FDA review via BLA submitted September 2025, offers dosing flexibility (once-weekly to once-monthly) and age coverage starting at one year, differentiating it from competitors like emicizumab and concizumab.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.